<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03938545</url>
  </required_header>
  <id_info>
    <org_study_id>RVT-1401-2001</org_study_id>
    <nct_id>NCT03938545</nct_id>
  </id_info>
  <brief_title>ASCEND GO-2: Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )</brief_title>
  <official_title>ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunovant Sciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunovant Sciences GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the current study is to assess the efficacy and safety/tolerability of three
      dose regimens of RVT-1401 in the treatment of active, moderate to severe GO patients. In
      addition, the study is designed to characterize the effect of RVT-1401 exposure on reduction
      in anti-TSHR IgG
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of safety by analysis of adverse events (AEs) data</measure>
    <time_frame>13 weeks</time_frame>
    <description>AE summaries of the number and percent of participants reporting each event at least once will be generated. Other safety data will be summarized descriptively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of proptosis responders in study eye without deterioration in fellow eye at the end of treatment</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proptosis responder rate</measure>
    <time_frame>Weeks 1-12, weeks 14-20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in proptosis</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Activity Score (CAS)</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with overall ophthalmic improvement</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Gorman Score for diplopia</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Graves' Ophthalmopathy Quality of Life (GO-QOL)</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with Clinical Activity Score (CAS) of 0 or 1</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Graves' Ophthalmopathy (GO)</condition>
  <arm_group>
    <arm_group_label>Regimen A-RVT-1401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen A= RVT-1401 680 mg weekly for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B-RVT-1401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen B= RVT-1401 340 mg weekly for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen C-RVT-1401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen C= RVT-1401 255 mg weekly for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RVT-1401 (Administered via subcutaneous injection)</intervention_name>
    <description>RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.</description>
    <arm_group_label>Regimen A-RVT-1401</arm_group_label>
    <arm_group_label>Regimen B-RVT-1401</arm_group_label>
    <arm_group_label>Regimen C-RVT-1401</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (Administered via subcutaneous injection)</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ≥ 18 years of age.

          2. Clinical diagnosis of Graves' disease with hyperthyroidism associated with active,
             moderate to severe GO with a Clinical Activity Score (CAS) ≥ 4 for the most severely
             affected eye at Screening and Baseline (on the 7-item scale).

          3. Onset of active GO within 9 months of screening.

          4. Moderate-to-severe active GO (not sight-threatening but has an appreciable impact on
             daily life), usually associated with one or more of the following: lid retraction ≥ 2
             mm, moderate or severe soft tissue involvement, proptosis ≥ 3 mm above normal for race
             and gender, and/or inconstant or constant diplopia.

          5. Other, more specific inclusion criteria are defined in the protocol

        Exclusion Criteria:

          1. Use of any steroid (IV, oral, steroid eye drops) for the treatment of GO or other
             conditions within 3 weeks prior to Screening. Steroids cannot be initiated during the
             trial. Exceptions include topical and inhaled steroids which are allowed.

          2. Use of rituximab, tocilizumab, or any monoclonal antibody for immunomodulation within
             the past 9 months prior to Baseline.

          3. Total IgG level &lt; 6g/L at Screening.

          4. Absolute neutrophil count &lt;1500 cells/mm3 at Screening.

          5. Participants with decreased best corrected visual acuity due to optic neuropathy as
             defined by a decrease in vision of 2 lines on the Snellen chart, new visual field
             defect, or color defect secondary to optic nerve involvement within the last 6 months
             at Screening.

          6. Previous orbital irradiation or surgery for GO.

          7. Other, more specific exclusion criteria are defined in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Central Study Contact</last_name>
    <phone>1-800-797-0414</phone>
    <email>clinicaltrials@immunovant.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Multispecialty Aesthetic Clinical Research Organziation (MACRO)</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Douglas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Doheny Eye Center UCLA</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rootman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wester</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan - Kellogg Eye Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nelson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Feldon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eye Wellness Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Schiffman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UW Health - University Station Clinic - Eye Care Services</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705-3644</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lucarelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z-1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dolman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto Retina Institute</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M3C 0G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Tucker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Eye Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jordan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ophthalmology University Center- Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hardy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitat Duisburg-Essen</name>
      <address>
        <city>Duisburg</city>
        <zip>47057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eckstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orbitazentrum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60318</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg-Universitaet Mainz Universitaets-Hautklinik</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kahaly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ARNAS Garibaldi, Presidio di Nesima</name>
      <address>
        <city>Palermo</city>
        <state>Catania</state>
        <zip>95122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Le Moli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Salvi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Endocrinologia 2, Azienda Ospedaliero-Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge, Carrer Feixa Llarga</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Catalonia</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Serrano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Oftalmologia Barraquer</name>
      <address>
        <city>Barcelona</city>
        <zip>08021</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lopez Fortuny</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sales-Sanz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 1, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IMVT-1401</keyword>
  <keyword>Graves' Orbitopathy</keyword>
  <keyword>Thyroid Eye Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graves Ophthalmopathy</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

